Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
An eight-week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in comparison with aliskiren 300 mg in patients with essential hypertension not adequately responsive to aliskiren 300 mg monotherapy https://kusajili.fr:443/Trial/FHmIe7U0-EC46tbcXL3ihQ%24an-eight-week-randomized-double-blind-parallel-group-multicenter-study-to-evaluate-the-efficacy-and-safety-of-the-combination-o
I have read and accept the terms of use of the site and the Privacy Policy
Send your message